Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene.


Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
04 2019
Historique:
received: 10 04 2018
revised: 20 07 2018
accepted: 15 08 2018
pubmed: 17 10 2018
medline: 24 5 2019
entrez: 17 10 2018
Statut: ppublish

Résumé

Unilateral vestibular schwannoma (VS) occurs with a lifetime risk of around 1 in 1,000 and is due to inactivation of the NF2 gene, either somatically or from a constitutional mutation. It has been postulated that familial occurrence of unilateral VS occurs more frequently than by chance, but no causal mechanism has been confirmed. Retrospective database analysis. The likelihood of chance occurrence of unilateral VS, or occurring in the context of neurofibromatosis type 2 (NF2), was assessed using national UK audit data and data from the national NF2 database. Families with familial unilateral VS (occurrence in first- and second-degree relatives) were assessed for constitutional NF2 and LZTR1 genetic variants, and where possible the tumor was also analyzed. Approximately 1,000 cases of unilateral VS occurred annually in the United Kingdom between 2013 and 2016. Of these, 2.5 may be expected to have a first-degree relative who had previously developed a unilateral VS. The likelihood of this occurring in NF2 was considered to be as low as 0.05 annually. None of 28 families with familial unilateral VS had a constitutional NF2 intragenic variant, and in nine cases where the VS was analyzed, both mutational events in NF2 were identified and excluded from the germline. Only three variants of uncertain significance were found in LZTR1. Familial occurrence of unilateral VS is very unlikely to be due to a constitutional NF2 or definitely pathogenic LZTR1 variant. The occurrence of unilateral VS in two or more first-degree relatives is likely due to chance. This phenomenon may well increase in clinical practice with increasing use of cranial magnetic resonance imaging in older patients. 2b Laryngoscope, 129:967-973, 2019.

Identifiants

pubmed: 30325044
doi: 10.1002/lary.27554
pmc: PMC6563429
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

967-973

Subventions

Organisme : Manchester National Institute for Health Research Biomedical Research Centre
Pays : International

Informations de copyright

© 2018 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of The American Laryngological, Rhinological and Otological Society, Inc.

Références

J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):764-7
pubmed: 10329751
J Med Genet. 2002 May;39(5):315-22
pubmed: 12011146
Q J Med. 1992 Aug;84(304):603-18
pubmed: 1484939
Otol Neurotol. 2005 Jan;26(1):93-7
pubmed: 15699726
J Med Genet. 2007 Jul;44(7):424-8
pubmed: 17307835
Clin Genet. 2007 Apr;71(4):354-8
pubmed: 17470137
J Neurosurg. 2008 Jan;108(1):92-6
pubmed: 18173316
Am J Med Genet A. 2012 Jan;158A(1):215-9
pubmed: 22105938
J Med Genet. 2015 Jun;52(6):422-4
pubmed: 25725045
J Med Genet. 2015 Aug;52(8):557-62
pubmed: 26104281
J Neurooncol. 2015 Nov;125(2):439-41
pubmed: 26342709
Neurology. 2017 Jan 3;88(1):87-92
pubmed: 27856782
Clin Genet. 2017 Nov;92(5):540-543
pubmed: 28295212
JAMA Neurol. 2017 Sep 1;74(9):1123-1129
pubmed: 28759666
Am J Med Genet. 1994 Oct 1;52(4):450-61
pubmed: 7747758
Laryngoscope. 1997 Sep;107(9):1176-80
pubmed: 9292599

Auteurs

D Gareth Evans (DG)

Department of Genomic Medicine, Manchester, United Kingdom.

Andrew J Wallace (AJ)

Department of Genomic Medicine, Manchester, United Kingdom.

Claire Hartley (C)

Department of Genomic Medicine, Manchester, United Kingdom.

Simon R Freeman (SR)

Department of Otolaryngology, University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, Manchester Universities NHS Foundation Trust, Manchester, United Kingdom.

Simon K Lloyd (SK)

Department of Otolaryngology, University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, Manchester Universities NHS Foundation Trust, Manchester, United Kingdom.

Owen Thomas (O)

Department of NeuroRadiology, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Patrick Axon (P)

Department of Otolaryngology, Addenbrooke's Hospital Cambridge, United Kingdom.

Charlotte L Hammerbeck-Ward (CL)

Department of Neurosurgery, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Omar Pathmanaban (O)

Department of Neurosurgery, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Scott A Rutherford (SA)

Department of Neurosurgery, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Mark Kellett (M)

Department of Neurology, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Roger Laitt (R)

Department of NeuroRadiology, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Andrew T King (AT)

Department of Neurosurgery, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.

Jemma Bischetsrieder (J)

Department of Genetics, Kaiser Permanente, Fontana, California, U.S.A.

Jaishri Blakeley (J)

Johns Hopkins Hospital, Baltimore, Maryland, U.S.A.

Miriam J Smith (MJ)

Department of Genomic Medicine, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH